160 related articles for article (PubMed ID: 35941004)
1. Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges.
Meunier A; Longworth L; Kowal S; Ramagopalan S; Love-Koh J; Griffin S
Value Health; 2023 Jan; 26(1):60-63. PubMed ID: 35941004
[TBL] [Abstract][Full Text] [Related]
2. Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.
Meunier A; Longworth L; Gomes M; Ramagopalan S; Garrison LP; Popat S
Pharmacoeconomics; 2023 Aug; 41(8):1011-1025. PubMed ID: 37296369
[TBL] [Abstract][Full Text] [Related]
3. Challenges and Limitations in Distributional Cost-Effectiveness Analysis: A Systematic Literature Review.
Steijger D; Chatterjee C; Groot W; Pavlova M
Int J Environ Res Public Health; 2022 Dec; 20(1):. PubMed ID: 36612824
[TBL] [Abstract][Full Text] [Related]
4. Incorporating Equity Concerns in Cost-Effectiveness Analyses: A Systematic Literature Review.
Ward T; Mujica-Mota RE; Spencer AE; Medina-Lara A
Pharmacoeconomics; 2022 Jan; 40(1):45-64. PubMed ID: 34713423
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis.
Kowal S; Ng CD; Schuldt R; Sheinson D; Cookson R
Value Health; 2023 Feb; 26(2):216-225. PubMed ID: 36192293
[TBL] [Abstract][Full Text] [Related]
6. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
[TBL] [Abstract][Full Text] [Related]
7. Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users.
O'Flaherty M; Lloyd-Williams F; Capewell S; Boland A; Maden M; Collins B; Bandosz P; Hyseni L; Kypridemos C
Health Technol Assess; 2021 May; 25(35):1-234. PubMed ID: 34076574
[TBL] [Abstract][Full Text] [Related]
8. An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective.
Meunier A; Opeifa O; Longworth L; Cox O; Bührer C; Durand-Zaleski I; Kelly SP; Gale RP
Eye (Lond); 2024 Mar; ():. PubMed ID: 38555401
[TBL] [Abstract][Full Text] [Related]
9. Modelled Distributional Cost-Effectiveness Analysis of Childhood Obesity Interventions: A Demonstration.
Killedar A; Lung T; Taylor RW; Hayes A
Appl Health Econ Health Policy; 2023 Jul; 21(4):615-625. PubMed ID: 37221341
[TBL] [Abstract][Full Text] [Related]
10. Equity and economic evaluation of system-level health interventions: A case study of Brazil's Family Health Program.
Love-Koh J; Mirelman A; Suhrcke M
Health Policy Plan; 2021 Apr; 36(3):229-238. PubMed ID: 33386400
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. Impact of Socioeconomic Differences on Distributional Cost-effectiveness Analysis.
Yang F; Angus C; Duarte A; Gillespie D; Walker S; Griffin S
Med Decis Making; 2020 Jul; 40(5):606-618. PubMed ID: 32608317
[TBL] [Abstract][Full Text] [Related]
13. Assessments of the Value of New Interventions Should Include Health Equity Impact.
Jansen JP; Trikalinos TA; Phillips KA
Pharmacoeconomics; 2022 May; 40(5):489-495. PubMed ID: 35237944
[TBL] [Abstract][Full Text] [Related]
14. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
[TBL] [Abstract][Full Text] [Related]
15. Distributional cost-effectiveness analysis in low- and middle-income countries: illustrative example of rotavirus vaccination in Ethiopia.
Dawkins BR; Mirelman AJ; Asaria M; Johansson KA; Cookson RA
Health Policy Plan; 2018 Apr; 33(3):456-463. PubMed ID: 29309581
[TBL] [Abstract][Full Text] [Related]
16. Using Cost-Effectiveness Analysis to Address Health Equity Concerns.
Cookson R; Mirelman AJ; Griffin S; Asaria M; Dawkins B; Norheim OF; Verguet S; J Culyer A
Value Health; 2017 Feb; 20(2):206-212. PubMed ID: 28237196
[TBL] [Abstract][Full Text] [Related]
17. Equity in HTA: what doesn't get measured, gets marginalised.
Cookson R; Mirelman AJ
Isr J Health Policy Res; 2017; 6():38. PubMed ID: 28694961
[TBL] [Abstract][Full Text] [Related]
18. Distributional impact of the Malawian Essential Health Package.
Arnold M; Nkhoma D; Griffin S
Health Policy Plan; 2020 Jul; 35(6):646-656. PubMed ID: 32361730
[TBL] [Abstract][Full Text] [Related]
19. Uncertainty Analysis in Intervention Impact on Health Inequality for Resource Allocation Decisions.
Yang F; Duarte A; Walker S; Griffin S
Med Decis Making; 2021 Aug; 41(6):653-666. PubMed ID: 34098791
[TBL] [Abstract][Full Text] [Related]
20. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
